Neuroprotection: extrapolating from neurologic diseases to the eye.
OBJECTIVE
To review the current status of neuroprotection in ophthalmic disease.


METHODS
Perspective.


METHODS
Published and unpublished data on neuroprotection in neurologic and ophthalmologic diseases were reviewed and interpreted.


RESULTS
Almost all clinical studies of neuroprotection in neurologic and ophthalmologic disease so far have failed to show efficacy, despite encouraging preclinical studies.


CONCLUSIONS
Achievement of consensus on how to design and execute translational research in neuroprotection in ophthalmic disease would optimize the use of resources and would hasten the development and approval of effective neuroprotective agents.
Danesh-Meyer
Helen V
HV
Department of Ophthalmology, University of Auckland Medical School, Auckland, New Zealand. helendm@gmail.com
Levin
Leonard A
LA
D000818:Animals; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D023381:Endpoint Determination; D018691:Excitatory Amino Acid Antagonists / Q000627:therapeutic use*; D005902:Glaucoma, Open-Angle / Q000517:prevention & control*; D006801:Humans; D008559:Memantine / Q000627:therapeutic use; D016202:N-Methylaspartate / Q000037:antagonists & inhibitors; D009422:Nervous System Diseases / Q000188:drug therapy*; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D009901:Optic Nerve Diseases / Q000188:drug therapy*; D019782:Riluzole / Q000627:therapeutic use
D018691:Excitatory Amino Acid Antagonists; D018696:Neuroprotective Agents; D016202:N-Methylaspartate; D019782:Riluzole; D008559:Memantine